Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC
Kim Nguyen, Rana R. McKay, Shahneen Sandhu, José Ángel Arranz, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D. Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E. Rathkopf (2025). rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator’s choice in patients with mCRPC. , 21(14), DOI: https://doi.org/10.1080/14796694.2025.2502318.
Article309 days agoA phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).
Kim N., Rana R. McKay, Shahneen Sandhu, José Ángel Arranz Arija, Philippe Barthélémy, Boris Hadaschik, Nobuaki Matsubara, Neal D. Shore, Dingwei Ye, Teresa Cascella, Irina Irincheeva, Stephanie Kreiser, Antoine Thiery-Vuillemin, Dana E. Rathkopf (2025). A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps5119.
Article309 days agoFinal Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial
Johann S. de Bono, He Meng, Zhen Shi, Małgorzata Nowicka, Sergio Bracarda, Cora N. Sternberg, Kim N., David Olmos, Shahneen Sandhu, Christophe Massard, Nobuaki Matsubara, Geng Chen, Nives Selak Bienz, Daniel Canter, Matthew Wongchenko, Christopher J. Sweeney (2025). Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. , DOI: https://doi.org/10.1016/j.eururo.2024.12.015.
Article309 days agoSupplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann S. de Bono (2023). Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). , DOI: https://doi.org/10.1158/1078-0432.22486373.
Preprint309 days agoSupplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)
Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, Allison Allen, Christian Poehlein, Johann S. de Bono (2023). Supplementary Figure from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). , DOI: https://doi.org/10.1158/1078-0432.22486379.
Preprint309 days ago